Cidara therapeutics, inc. (CDTX)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer

20,915

0

0

-

-

-

-

Operating expenses:
Research and development

46,401

49,142

42,823

35,699

23,475

6,710

810

Cost of in-process research and development acquired

-

-

-

-

-

1,607

-

General and administrative

16,238

14,143

12,898

12,737

8,838

3,306

272

Total operating expenses

62,639

63,285

55,721

48,436

32,313

11,623

1,082

Loss from operations

-41,724

-63,285

-55,721

-48,436

-32,313

-11,623

-1,082

Other income (expense):
Gain (Loss) on Derivative Instruments, Net, Pretax

400

3,900

0

0

-

-

-

Interest income, net

221

629

-7

271

120

-88

-95

Other expense

0

211

0

0

-

-

-

Change in fair value of convertible notes payable

-

-

-

-

-

-183

-167

Total other income (expense)

632

4,269

-7

271

120

-271

-

Total other income (expense)

-

-

-

-

-

-

-262

Net loss and comprehensive loss

-41,092

-59,016

-55,728

-48,165

-32,193

-11,894

-1,344

Recognition of beneficial conversion feature

0

10,329

0

0

-

-

-

Net loss attributable to common shareholders

-41,092

-69,345

-55,728

-48,165

-

-

-

Basic and diluted net loss per common share (USD per share)

-1.41

-2.76

-3.18

-3.32

-3.25

-14.51

-4.15

Shares used to compute basic and diluted net loss per common share (in shares)

29,093

25,142

17,500

14,488

9,920

819

323

Net Income (Loss) Attributable to Parent

-41,092

-59,016

-55,728

-48,165

-

-

-

Unrealized gain (loss) on short-term investments

0

8

-7

-

-

-

-

Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

-

-

-

7

-8

0

-

Comprehensive loss

-41,092

-59,008

-55,735

-48,158

-32,201

-11,894

-1,344